Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Atezolizumab + BKT140
Indication/Tumor Type pancreatic ductal adenocarcinoma
Response Type no benefit

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown pancreatic ductal adenocarcinoma no benefit Atezolizumab + BKT140 Phase Ib/II Actionable In a combined analysis of 2 Phase I/II trials, Tecentriq (atezolizumab) and BL-8040 (BKT140) combination therapy demonstrated expected toxicity profile and limited efficacy, did not improve objective response rate (0/14 vs 0/15), median progression-free survival (1.6 vs 2.5 mo), or median overall survival (5.2 vs 6.8 mo) compared to control in patients with metastatic pancreatic ductal adenocarcinoma (J Clin Oncol 38, 2020 (suppl 4; abstr 712); NCT03281369, NCT03193190). detail...
PubMed Id Reference Title Details
Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC). Full reference...